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 INI1 (Integrase Interactor 1) is a highly-conserved, core component of the SWI/SNF 
remodeling complex and is characterized as a tumor suppressor. Mutations in the SMARCB1 
gene/INI1 protein cause aggressive pediatric cancers called malignant rhabdoid tumors (MRT). 
Atypical Teratoid/Rhabdoid Tumors (AT/RT), a common form of MRT, are a pediatric cancer 
associated with INI1 mutations and form in the central nervous system and kidneys of infants. 
Although the tertiary structure of INI1 is unknown, the 385 amino acids-long protein contains an 
N-terminal DNA binding domain (1-186), two imperfect repeat regions (187-245 and 259-319) 
that could mediate protein-protein interactions, and a C-terminal coiled-coil domain (334-376). 
Little is understood about INI1’s function, structure, regulation, or DNA binding. To determine 
INI1’s minimal binding domain, INI1(31-125) and INI1(31-144) were expressed in E. coli cells. 
The 6X His-tagged truncations did not bind to the Ni-NTA resin, necessitating the use of binding 
tests. The results of this study conclude that the INI1 truncations did not bind to the Ni-NTA 
resin under any tested conditions, indicating that further attempts need to be made at finding the 
correct binding condition and ensuring that a functional 6X His-tag is present. In future studies, 
the purified INI1(31-125) and INI1(31-144) fragments will be used in DNA binding assays to 
determine if these fragments contain INI’s minimum binding domain.  
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 All the genetic information in a cell is encoded in its deoxyribonucleic acid (DNA). All 
known cellular life and some viruses contain DNA as their long-term information storage 
molecule. The human genome consists of roughly three billion base pairs that comprise 23 
chromosomes [1]. DNA is a long polymer of deoxynucleotides connected by phosphodiester 
linkages that contains coding sequences called genes, structural segments, and regulatory 
sequences. The information encoded in genes instructs the cell on how to make proteins and 
other cellular components that are vital to life. Various proteins and enzymes interact with DNA 
to regulate gene expression and cellular activities. Careful regulation of gene expression is 
necessary to maintain a healthy, functioning cell. 
 
Chromatin  
 If the DNA of one human cell was linearized and placed end-to-end, it would be 
approximately 6 feet (1.8 meters) in length [1]. Because of the vast amount of DNA present in 
each eukaryotic cell, the cell must find an efficient way to pack this information safely into a 
nucleus. In addition, the packing mechanism must allow DNA access to various proteins 
associated with gene regulation, protein expression, DNA repair, and cellular division. The cell 
accomplishes this feat by storing DNA in a highly-condensed structure called chromatin. 
 A mononucleosome is the simplest unit of chromatin and contains approximately 147 
base pairs of DNA wound around a positively-charged protein octamer called a histone. Each 
histone complex is formed by two copies of the core histones H2A, H2B, H3, and H4, and a 
linker histone H1 that is bound to DNA between the nucleosomes [2]. Nucleosomes occur 
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roughly every 200 base pairs along the DNA strand, and the H1 linker histone is thought to 
facilitate the formation of nucleosome 3-dimensional structure [3].  
 The two main types of chromatin are euchromatin and heterochromatin, which perform 
different functions within the genome. Euchromatin is a less-dense, unfolded structure 
containing the active genes that are frequently transcribed in a genome. The nucleosomes of 
euchromatin are spread further apart, making the DNA more accessible for gene regulatory 
proteins and polymerases to bind [4]. Histones are post-translationally modified to regulate gene 
expression [5]. Examples of these epigenetic modifications include methylation, acetylation, and 
phosphorylation of the H3 core histone protein. These covalent histone modifications signal the 
expression or silencing of a gene. For example, acetylation, specific to euchromatin, is defined as 
the reversible addition of an acetyl (C2H3O) group to the positively-charged amino R group of 
lysine residues in histones [6]. The addition of an acetyl group by histone acetyl transferases 
(HAT) neutralizes the positive charge of the histones, reducing the binding affinity between the 
histones and the negatively-charged DNA. This allows the DNA to unwind from the histones and 
be more accessible to transcription machinery [6].  
 Heterochromatin is a highly-condensed form of DNA and constitutes a much smaller 
portion of the human genome [7]. There are two forms of heterochromatin that perform different 
functions. Constitutive heterochromatin contains repetitive stretches of DNA that form structural 
DNA components, such as telomeres and centromeres, which aid in chromosomal segregation 
during cell division. Constitutive heterochromatin is generally highly-methylated which renders 
it transcriptionally silent [7]. Facultative heterochromatin also contains genes that are silenced 
due to histone deacetylation or methylation. Although these genes are silenced, they influence 
the expression of other genes during certain periods of development and silences the genes that 
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are no longer needed. For example, facultative chromatin is found in inactive X chromosomes in 
female mammals and facilitates dose compensation to ensure that there is equal expression of X-
linked genes in males and females [5]. 
 
ATP-Dependent Chromatin Remodeling 
 Nucleosomes are an effective way to pack and preserve DNA, but they block the binding 
of proteins needed for DNA repair, replication, and transcription. Chromatin remodeling is the 
conformational modification of chromatin to allow access for this machinery, which promotes 
DNA repair and gene expression. Chromatin remodeling is performed by ATP-dependent 
chromatin remodeling complexes that reposition nucleosomes. These complexes can remove 
histones and reposition the nucleosomes to expose the DNA for DNA repair, replication, and 
transcription machinery binding [8]. 
 There are five identified families of chromatin remodeling complexes in eukaryotes: 
SWI/SNF, ISWI, INO80, SWR1, and NuRD/Mi-2/CHD. Each complex contains its own unique 
protein domains that are specific to the complex’s function; however, each complex contains a 
catalytic ATPase domain that hydrolyzes ATP and uses the energy gained to perform its assigned 
function [9]. 
 
The SWI/SNF Chromatin Remodeling Complex 
SWI/SNF (SWItch/Sucrose Non-Fermentable), first discovered in yeast, is an 
evolutionarily-conserved, eukaryotic multi-subunit chromatin remodeling complex that uses 
ATP to alter the position of nucleosomes, thus regulating transcription. The large 2MDa complex 
consists of at least nine protein subunits, including conserved and non-conserved proteins. The 
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four essential and conserved core subunits for chromatin remodeling are BRG1, INI1, BAF155, 
and BAF170 [10]. The other variable subunits might assist in directing specificity of the 
SWI/SNF complex by protein-protein interactions. The variable subunits incorporated depend on 
the tissue type, suggesting that these proteins have functions based on the needs of the specific 
cell type [10]. 
SWI/SNF’s ATPase domain is in the BRG1 protein subunit [10]. The energy extracted 
from the hydrolysis of ATP allows SWI/SNF to slide the histones down the DNA strand or 
remove them completely. The exact mechanism of how SWI/SNF remodels chromatin is 
unknown due to the highly-intricate interactions between SWI/SNF, histones, DNA, and other 
associated proteins [11]. The BRG-1 subunit also contains a bromodomain, which is important in 
recognition and binding of acetylated lysine residues on histone tails [10]. 
The SWI/SNF complex binds to the minor groove of DNA when a specific set of DNA 
modifications are identified [12]. The complex possesses a large amount of DNA binding motifs 
because of the binding requirements of the various, non-core subunits [13].  More recent studies 
have suggested that SWI/SNF could also bind to DNA nonspecifically, which allows the 
complex to tightly bind to the nucleosome for efficient remodeling [13].  
 SWI/SNF still has many mysteries including its exact mechanism, its possible 
involvement in other cellular processes, and its associated proteins and their functions. These 
gaps in knowledge must be determined before researchers can begin treating SWI/SNF 
deficiencies. It is thought that the mammalian SWI/SNF complex acts as a tumor suppressor 
because various human cancer cell lines lack either the whole complex or one of its subunits 




 Integrase Interactor 1 (INI1) (also known as SNF5, BAF47, and hSNF5) is one of the 
four core, conserved subunits in the SWI/SNF complex. The human SMARCB1 (SWI/SNF-
related, matrix-associated, actin-dependent regulator of chromatin, subfamily b, member 1) gene 
codes for INI1 and is located on the long arm of chromosome 22 at the 22q.11.23 position. The 
gene contains nine exons that encode 385 amino acids and weighs approximately 47kDa [15]. 
INI1 is largely acidic, containing 27.5% charged residues. There are four identified isoforms in 
the human body but their distinct functions are unknown [15]. The isoform studied in this 
laboratory is Isoform B, which is 376 amino acids-long and is missing the 69th-77th amino acids 
of full-length INI1 (Isoform A). INI1 is highly-concentrated in the nucleus but is also observed 
in small amounts in the cytoplasm. INI1 is expressed in all tissue types with the highest 
prevalence in rapidly dividing tissues such as the testis, liver, lymph nodes, and brain [16]. 
 There are four distinct, essential regions of INI1 that have been identified in all isoforms, 
shown in Figure 1 [17]. The potential DNA binding domain at the N-terminus spans from amino 
acids 1-186 and is highly basic with a pI of 9.3 [17]. The first imperfect repeat region (Rpt I) 
spans amino acids 186-245, while the second imperfect repeat region (Rpt II) spans amino acids 
259-319. These sixty-amino-acid-long stretches are highly-charged and are thought to be 
involved in protein-protein interactions with c-MYC and HIV Integrase [18]. Rpt II contains a 
nuclear export sequence that allows INI1 to complete non-nuclear signaling[17, 19]. The C-
terminal of the protein, spanning amino acids 334-376, forms a leucine-rich coiled-coil 





The large number of aliases of INI1 indicates that INI1 is evolutionarily conserved as it 
has been identified in other organisms including Drosophila (BAF), Saccharomyces/yeast 
(SNF5), and humans (SMARCB1). Although its exact function is unknown, knockout studies of 
INI1 in murine models indicate that INI1 is essential for embryonic development as embryos 
lacking INI1 do not survive past the pre-implantation stage [20].  
  
INI1 Mutations and Effects 
 Mutations of the SMARCB1 gene that cause a deletion or altered form of INI1 result in 
the development of rhabdoid predisposition syndrome [15]. This condition leads to increased risk 
of developing a highly lethal form of pediatric cancer called malignant rhabdoid tumors (MRT) 
[14]. MRTs are a rare but highly aggressive form of pediatric cancer that is prevalent in the 
kidneys, brain, and spinal cord of infants with mutations in the SMARCB1 gene. These tumors 
often quickly metastasize to the lymph nodes and lungs [15]. In mouse models, inactivation of 
the INI1 gene resulted in 100% of the test mice developing this form of cancer, strongly 
suggesting that functioning INI1 acts as a tumor suppressor [15]. A wide variety of mutations 
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have been associated with the development of MRTs including total homozygous deletions of 
the SMARCB1 gene, truncations of various exons, missense mutations, nonsense mutations, 
base-substitutions, and single-base deletions resulting in frameshifts [21, 22].   
 A specific type of MRTs called Atypical/Teratoid Rhabdoid Tumors (AT/RT) are the 
result of a de novo germline mutation of the SMARCB1 gene. In these cases, the parents have 
two copies of the wildtype SMARCB1 allele, but a mutation occurs during embryogenesis due to 
a flaw in one of the gamete’s genome [23]. These tumors are characterized as highly aggressive 
and typically are seen in the central nervous system of children three-years-old or younger. Due 
to multiple risk factors including the aggressive nature of the cancer, the young age of the 
patients, the harsh side-effects of chemotherapy, and the tricky placement of the tumors, there is 
currently no fully- effective treatment protocol for AT/RT tumors. Because of these reasons, the 
two-year survival rate after diagnosis is less than 20% and the average post-diagnosis lifespan is 
11 months [24].  
 Additional studies have also linked SMARCB1/INI1 mutations to tumors such as 
epithelioid sarcomas, schwannomas, and synovial sarcomas [25]. Although INI1disruption has 
been identified as a causal factor in these cancers, the native INI1 function and the mutated INI1 
mechanism are still unknown. Therefore, researchers need to determine how INI1 functions, how 
it is regulated, and what it affects to provide insight on the role of INI1 in cancerous cells. The 
eventual goal of this vast body of research is to find an effective treatment and cure for the 







DNA-binding proteins function by forming noncovalent bonds with DNA to either 
regulate its expression or change its confirmation to make the gene targets more accessible. 
These noncovalent interactions include hydrogen bonding, Van Der Waals interactions, and ionic 
bonding, which bind the protein to the DNA. These interactions occur on the DNA-binding 
domain of the protein, a conserved fragment that binds to a specific sequence of modifications on 
the DNA strand. The protein DNA-binding domains are typically found on the exterior of the 
protein so it has full access to the target DNA sequence [26]. 
Previous research conducted in Dr. Ruhl’s laboratory determined that a portion of INI1 
binds to DNA, suggesting that INI1 contains a DNA-binding domain. A previous graduate 
student, Dustin Steele (2013-2016), started the project of determining what region of INI1 binds 
to DNA. To begin, he cleaved the full-length 376 amino acid-long INI1 Isoform B into two 
pieces. The INI1(1-186) truncation demonstrated the ability to nonspecifically bind to “naked” 
DNA (DNA that is not wrapped around histones) as well as mononucleosomes [17]. The 
INI1(187-385) truncation did not demonstrate the ability to bind to either naked DNA or 
mononucleosomes, narrowing the search for DNA-binding regions to the first half of the protein 
[17]. Further unpublished data from Steele showed that INI1(1-144) does bind to both naked 
DNA and mononucleosomes, while INI1(63-144) does not bind to either naked DNA or 
mononucleosomes [27]. To further narrow the search for the minimum DNA binding domain, 
plasmids of INI1(31-125) and INI1(31-144) were created. These fragments were chosen based 
on their presence in tumor cells of AT/RT patients and further cleavage of the previously 





 The goal of this research project was to express and purify two potential DNA binding 
domains of INI1, INI1(31-125) and INI1(31-144), and determine if these two regions bind to 
DNA. If either one of these truncations is the minimum DNA-binding domain of INI1, 
researchers can use this information to determine the function of INI1 and understand how 
mutations in INI1 lead to pediatric cancer.  





 INI1(31-125) and INI1(31-144) had previously been cloned and transformed into the 
pSKB3 E. coli vector with a Kanamycin resistance gene insert generously provided by Dr. 
Deng’s laboratory. Two separate variants of each truncation were made: one with the 6X His-tag 
on the C-terminus and one with the 6X His-tag on the N-terminus. Each of the four variants was 
expressed with the same procedure. Cells were picked from the cryovial and placed in 100mL of 
autoclaved Luria Broth (1% tryptone, 0.5% yeast extract, 1% NaCl, dH2O, and 10mg/mL 
kanamycin) to incubate at 30°C at 250rpm overnight. This is the overnight culture. Then, 0.3mL 
of Kanamycin stock solution was added to the media to kill any contaminating cell that did not 
have the kanamycin insert.  
 Ultraviolet-visible (UV) Spectroscopy was used to read the optical density (OD) at λ=600 
nm, which quantifies the concentration of cells in the medium by measuring the amount of light 
that is deflected by the cells. A higher OD number signifies a higher concentration of cells. One 
mL of overnight culture was added to 400mL of fresh Luria Broth and the OD was read. If the 
sample was below an OD of 0.06, another milliliter of overnight culture was added until the 
desired OD was reached. An OD of 0.06 suggests that the E. coli were about to enter the log 
phase of growth. The flasks were incubated at 37°C and 250rpm until the OD reached 0.6. An 
OD of 0.6 was chosen to ensure that the E. coli were in the logarithmic phase of growth as this 
phase is ideal for protein expression. At this point, the flasks were removed from the shaker and 
allowed to cool to room temperature. Once cool, the flasks were transferred to a refrigerated 
shaker at 18°C and 250rpm. The INI1 truncation expression was induced by adding 400µL of 
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isopropyl-β-D-1-thiogalactopyranoside (IPTG) to each flask. The flasks were left in the 
refrigerated shaker overnight to allow protein synthesis. 
 The flasks were removed from the refrigerated shaker 18-22 hours after induction. The 
cells were spun down into a pellet using a GSA rotor made for the DuPont Sorvall RC-5B 
Superspeed Centrifuge at 4,000rpm for 30 minutes. The supernatant was discarded, and the 
pellets were stored at -80°C.  
 
Protein Purification 
 All protein truncations were purified in a similar manner. Thawed pellets were suspended 
in 20mL of Buffer A (20mM Tris, 500mM NaCl, 10% Glycerol, 20mM Imidazole, pH 7.8), 
vortexed until dissolved in buffer, then placed on ice. To rid the sample of some possible 
contaminants, lysozyme and DNase were added. Ten milligrams of dehydrated lysozyme were 
dissolved in 1mL of dH2O and left on ice for 40 minutes before adding to each pellet. Each pellet 
received 5µL of Invitrogen Amplification Grade DNase I before sonication. Each pellet sample 
was poured into a 50mL glass beaker and kept on ice. The samples were sonicated in 10-second 
cycles for a total time of two minutes. The combination of salt in Buffer A and the bombardment 
of sound waves produced by the sonicator burst the cell membranes, releasing all cellular 
contents, including the protein of interest. The samples were centrifuged in a SA-600 rotor made 
for the DuPont Sorvall RC-5B at 12,000rpm for 30 minutes at 4°C.  The supernatant containing 
the cellular contents was collected in 50mL falcon tubes and stored at -80°C until further 
purification. A 50µL sample of each supernatant was collected in a 1mL microfuge tube, labeled 
as “cell extract,” and placed in the -80°C freezer. 
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 The 6X poly-histidine tail (6X His-tag) on either terminal was added because of its high 
affinity and specificity to Ni-NTA agarose resin for affinity column chromatography. The Ni-
NTA resin was pre-equilibrated with Buffer A. After equilibration, 200µL of Ni-NTA resin was 
transferred to each falcon tube of supernatant (about 25mL) using a p1000 pipetman with 
roughly ½ cm of the tip cut off to not break the resin molecules. The supernatant and resin were 
rocked for one hour at 4°C, then poured over a 25mL gravity flow column to collect the resin 
and allow the liquid to flow through. If the 6X His-tag is not hidden within the protein, it should 
bind to the resin and stay on the column while proteins without the 6X His-tag or a similar 
highly-positive region flow through into the collection tube. The column was washed with 
100mL of 4°C Buffer A to wash off any unbound protein that was caught in the resin. A portion 
of the flow-through was pipetted back into the binding falcon tube to wash off any remaining 
resin and was poured back on the column. All flow through and wash samples were collected 
and stored in -80°C. Ten milliliters of Buffer B (20mM Tris, 500mM NaCl, 10% Glycerol, 
250mM Imidazole, pH 7.8) was pipetted carefully over the column to not disturb the resin. The 
high imidazole concentration in Buffer B has a high affinity for the binding regions on the resin 
and knocks the 6X His-tagged proteins off the resin. From this step, ten 1mL fractions were 
collected.  
 To ensure the isolation and purification steps worked, a 15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) was used. The SDS added to the sample 
denatures the proteins and coats the proteins in a negative charge, allowing the gel 
electrophoresis to separate by molecular weight only. Using the calculated molecular weight of 
the protein, it is possible to determine if the protein of interest is present. A 19µL sample was 
taken from the cell extracts, flow-through samples, wash samples, and each elution fraction (1-
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10). To each 19µL sample, 5µL of 10% SDS and 8 µL of 4X sample buffer (0.25M Tris-Cl, 
pH=6.8, 2% SDS, 10% β-mercaptoethanol, 20% glycerol, 0.01% bromophenol blue) were added. 
Each sample was boiled for 60 seconds and 20µL of each sample was loaded onto the 
acrylamide gel. Ten microliters of BioRad Precision Plus unstained protein standard molecular 
weight ladder were also loaded on the gel. The gel was run at 150V for one hour at room 
temperature. After running the gel, the stacking gel was cut off, and the gel was rocked in dH2O 
three times for ten minutes each to remove the Running Buffer. Thermo Fisher Scientific 
GelCode™ Blue was used to stain the gel. Imaging was performed with a BioRad ChemDoc™ 
XRS+ and a white light conversion tray. 
 
Purification Optimization Tests 
 After analyzing the N-terminus 6X His-tag variants of INI1(31-125) and INI1(31-144), 
flow-through samples from these variants were used to complete binding tests to determine if the 
proteins would bind under different conditions. Only the INI1(31-144) variant was used as it was 
assumed that both protein variants would react similarly.  
 For the first binding test, 40µL of INI1(31-144) flow-through sample were placed in each 
microfuge tube with 10µL of Ni-NTA pre-equilibrated with Buffer A. A control sample was set 
aside containing only flow-through (suspended in Buffer A from purifications steps) and resin. 
The second condition halved the concentration of the buffer by adding 40µL of dH2O. The third 
condition added 40 µL of 8M urea lysis buffer (100mM Phosphate, 10mM Tris-Cl, 8M Urea, pH 
8.0). The fourth condition added 1.2µL of 10% SDS (to a total SDS concentration of 0.3%). The 
fifth condition added 1µL of Tween 20 (to a total Tween 20 concentration of about 2%). The 
sixth condition added 1µL of Tween 80 (to a total Tween 80 concentration of about 2%). The 
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seventh and final condition added 1µL of Triton X-100 (to a total Triton-X concentration of 
about 2%). The samples rocked overnight at 4°C.  
 All seven condition tubes were put in a microfuge and spun to 4,000rpm two times. 
Using a P200 gel-loading tip, the liquid was removed from each resin tube and placed in a fresh, 
sterile microfuge tube, creating the supernatant tubes. The resin tubes were washed with 50µL of 
dH2O by flicking the tube to mix the resin with the water. This step washes away unbound 
proteins that could have become trapped between the resin beads. The wash was discarded. To 
each of the resin tubes, 5µL of 10% SDS and 8 µL of 4X sample buffer were added. For each of 
the supernatant tubes, 19µL of supernatant was transferred to a new microfuge tube and were 
mixed with 5µL of 10% SDS and 8 µL of 4X sample buffer. All samples were boiled for one 
minute. 
 To visualize if the protein bound to the resin or stayed in the supernatant, all samples 
were run on a 15% SDS-PAGE gel. From the liquid supernatant tubes, 20µL were loaded onto 
the gel using gel-loading tips. For the resin sample tubes, all liquid in the tube and some resin 
were loaded onto the gel using a P200 tip. Ten microliters of BioRad Precision Plus unstained 
protein standard molecular weight ladder were also loaded on the gel. The gel was run at 150V 
for one hour at room temperature. After running the gel, the stacking gel was cut off, and the gel 
was rocked in dH2O three times for ten minutes each to remove the Running Buffer. Thermo 
Fisher Scientific GelCode™ Blue was used to stain the gel. Imaging was performed with a 
BioRad ChemDoc™ XRS+ and a white light conversion tray. 
 For the second binding test, adjustments were made to see if they made a difference in 
binding. The procedure was consistent with the first binding test written above; therefore, only 
procedural changes will be listed below. Only four conditions of the previous conditions were 
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tested again: control, half-concentration of Buffer A, urea, and 10% SDS. These samples were 
prepared with the exact same conditions as the previous run. A new lane containing 40µL of N-
terminal 6X His-tag INI1(31-125) flow-through and 10µL of resin was added to test if the 
correct variant was present. The samples were rocked in 4°C for 1.5 hours and were mixed by 
flicking every 15 minutes to ensure that the solution was well-mixed. Instead of washing with 
dH2O, all resin samples were washed with 500µL of Buffer A to remove unbound proteins and 
the wash was removed with a gel-loading tip. Sample prep did not change. All samples, 
including resin samples, were loaded onto the 15% SDS-PAGE gel using gel-loading tips to 
prevent spill over. The gel was run, processed, and visualized using the same methods as above. 
 
Results 
Protein Expression and Purification 
 A 15% SDS-PAGE gel was used to assess the presence and purity of the INI1(31-125) 
and INI1(31-144) fragments. The first lane of each purification gel contains the cell extract. The 
cell extract sample includes all the proteins expressed by the E. coli and should, therefore, have a 
wide assortment of bands of varying concentrations and molecular weights. Because the E. coli 
contain a plasmid that codes for the desired truncations of INI1, the cell extract lane should have 
a highly-concentrated band around the molecular weight of the INI1 truncation if the protein was 
properly expressed.  
The second lane of each gel contains the flow-through sample collected following the 
loading of the cell extract onto the resin. The positively-charged 6X His-tag on the termini of 
INI1 binds to the negatively-charged resin while the other cellular components flow through. If 
the 6X His-tag is positioned on the exterior portion of the INI1 truncation where it is free to bind 
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to the resin, the flow-through sample should contain all proteins from the cellular extract except 
for the 6X His-tagged INI1.  
The third lane of each gel contains the wash sample obtained after running Buffer A over 
the column to wash off any unbound protein. This lane is expected to have bands of various 
molecular weights. Because the wash sample dilutes the protein in 100 mL of Buffer A, faint 
bands are expected.  
Elution fractions 1-10 were taken after running Buffer B over the column and were 
loaded on the gel. Buffer B contains a high concentration of imidazole which is part of the side 
chain of the Histidine residues that make up the 6X His-tag. When high concentrations of 
imidazole interact with the resin, it competes with the 6X His-tag for binding sites and causes the 
His-tagged protein to fall off the resin and into the elution tube. Therefore, these fractions should 
contain a strong band around the molecular weight of the protein of interest and little to no other 
bands. Bands other than the protein of interest indicate that the elution sample is not pure and 
will need further purification techniques to completely purify the sample. 
 Theoretical molecular weights of the protein fragments were determined by the molecular 
weight calculator provided by ExPASy.org. INI1(31-125) has a molecular weight of 10,990Da 
and INI1(31-144) has a molecular weight of 13,034Da. The 6X His-tag contains six histidine 
residues and additional linker amino acids. If the 6X His-tag is added to the N-terminus, it 
contains 20 linker amino acids and weighs 2,096Da. If the 6X His-tag is added to the C-
terminus, it contains 22 linker amino acids and weighs 2,419Da. The exact linker amino acid 
sequences of the 6X His-tag are shown in Appendix 1, provided by Novagen. Adding the 6X 





Truncation 6X His-tag Location Molecular Weight (Da) 
INI1(31-125) N-terminus 13,086 
INI1(31-125) C-terminus 13,409 
   
INI1(31-144) N-terminus 15,130 
INI1(31-144) C-terminus 15,453 
 
A dark band around these molecular weights on the gel could indicate the presence of the 
INI1 truncation. It is also important to note the level of uncertainty of SDS-PAGE. On SDS-










Figure 2 and Figure 3 show the expression and purity of the N-terminal 6X His-tagged 
INI1(31-125) and INI1(31-144) truncations, respectively. Figure 2 shows no strong bands around 
13kDa in the elution fractions. In both Elution 1 lanes on both gels, there are very light bands 
around the correct molecular weights of the proteins that could be the protein of interest that are 
not observed in other lanes. There are dark bands around 13kDa in the cell extract fraction lane 
and the flow-through fraction lane (indicated by the box). Figure 3 shows similar results as no 
prominent bands are present around 15kDa in the elution fractions. Dark bands are present in the 
cell extract fraction lane (indicated by the box) and the flow-through fraction lane around 15kDa. 
The elliptical marks on both gels are due to dye bubbles becoming trapped under the gel after the 







 Figure 4 and Figure 5 show the expression and purity of C-terminal 6X His-tagged 
INI1(31-125) and INI1(31-144) truncations, respectively. The results for the N-terminal 6X His-
tagged INI1 gels are consistent with the results from the C-terminal 6X His-tag INI1 gels. In 
both C-terminal 6X His-tagged INI1 gels, a very light band at the correct molecular weight is 
present in the Elution 1 lanes only. Both cell extracts and the flow-through samples show a dark 





Purification Optimization Tests 
 To determine if the INI1 truncations would bind to the Ni-NTA resin under different 
conditions, binding tests were conducted. The flow-through samples from protein expression 
methods were mixed with the pre-equilibrated resin and the variable component. After allowing 
time for binding, the supernatant was removed from each tube and the remaining resin beads 
were boiled. When Ni-NTA resin is boiled for one minute after adding the sample prep 
materials, the resin-bound proteins unbind and solubilize into solution. If the protein did not bind 
to the resin, a strong band should appear in the supernatant sample. If the protein did bind to the 
resin, a strong band should appear in the resin sample.  
 For the binding tests, only INI1(31-144) was used. It was assumed that if one condition 
worked for INI1(31-144), it would also work for INI1(31-125) because they are similar in size, 










 The first binding test in Figure 6 has significant distortion of lanes 1-3 and 11-15, 
rendering them unreadable. The remaining lanes show a multitude of bands in each lane as well 
as a strong band slightly under 15kDa. Some of the resin sample lanes look identical to their 
supernatant samples but are slightly fainter. Due to these results, the second binding test 
illustrated in Figure 7 was conducted. Figure 7 shows highly-concentrated samples in lanes 1-5. 
Lane 5, which contains the N-terminal 6X His-tagged INI1(31-125) sample has a dark band 
under 15kDa that is a smaller molecular weight than the heaviest band in lanes 1-4. Additionally, 




Protein Purification and Expression 
 The purpose of these four gels was to determine the presence and purity of the INI1 
truncations. In Figure 2 and Figure 3, only very faint bands with the correct molecular weight of 
the N-terminal 6X His-tagged INI1 truncations were found in the elution 1 sample lanes. 
However, there are strong bands slightly under the 15kDa marker in both the cell extract and 
flow-through samples of both the INI1(31-125) and INI1(31-144) gels (indicated by boxes). This 
finding suggests that although the protein was highly expressed by the E. coli, the protein only 
slightly bound to the resin and a predominate portion of the protein flowed-through the column 
with the rest of the cellular proteins.  
 Another method can be used to determine the approximate molecular weight of a protein 
band on the gel. A standard curve can be made by measuring how far each of the molecular 
weight ladder bands migrated from the top of the gel. These measurements create a standard 
curve and a trendline equation. To approximate the molecular weight of the proteins on the gel, 
the migratory distance of the band is measured in centimeters and plugged in for the X value of 
the equation. A sample standard curve and trendline equation for N-terminal 6X His-tagged 
INI1(31-144) from the gel in Figure 3 are shown in Figure 8. In this example, the strong bands in 
the cell extract and flow-through samples in Figure 3 are 3.85cm from the top of the gel. 
Plugging 3.85 into the trendline equation yields a molecular weight of 14,885Da which is about 
250Da smaller than the theoretically calculated 15,130Da molecular weight of N-terminus 6X 
His-tagged INI1(31-144). Although this mathematical approximation method is often close to the 
theoretical value, it does have its limitations. If the R2 value is less than 0.985, molecular weights 
begin shifting from theoretical values by up to 1,000Da. In addition, the accuracy of the standard 
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For the INI1(31-125) gel in Figure 2, the highly-concentrated bands in the cell extract 
and flow-through lanes and the light band in elution sample 1 are slightly below 15,000Da. The 
standard curve for this gel is poor as the R2 value is 0.982 and the approximation for the 
molecular weight is 15,004Da. Because the N-terminal 6X His-tagged INI1(31-125) protein is 
approximately 13,086Da, it is possible that this prominent band is our protein of interest. This is 
consistent with the light band observed in Elution sample 1. For the N-terminal 6X His-tagged 
INI1(31-144) gel in Figure 3, the highly concentrated bands in the cell extract and the flow-
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through and the light band in the elution 1 lane are below 15,000Da. The N-terminal 6X His-
tagged INI1(31-144) protein should be around 15,130Da which leads to three possible 
explanations for the difference in molecular weights. The first possible explanation is that this is 
not the protein of interest. Although the darkest band appears to be around the same molecular 
weight as the desired protein, it is possible that this is not the desired protein. The second 
possible explanation is that the protein might not be made correctly. The INI1(31-144) protein 
weighs 13,034Da before the 6X His-tag is added. The dark bands of the cell extract and flow-
through samples in Figure 3 lie around roughly 14,000Da; therefore, this could indicate that this 
is the protein of interest but the 6X His-tag is not present. The third possible explanation is that 
the shift is caused by the uncertainty of SDS-PAGE gels. As mentioned before, bands on gels 
can shift up to 2,000Da from their correct molecular weights depending on the properties of the 
gel and materials [28].  
 The gels in Figure 4 and Figure 5 show the presence and purity of the C-terminal 6X His-
tagged INI1 truncations. These gels show identical results to the gels from the N-terminal 6X 
His-tagged INI1 truncations. Again, there are highly-concentrated bands in the cell extract and 
flow-through samples but only very faint bands near the molecular weight of the protein of 
interest in the elution 1 sample lanes. Figure 4 of C-terminus 6X His-tagged INI1(31-125) shows 
dark bands in the cell extract and flow-through that are slightly under 15kDa (std curve = 
15,469Da), indicating that the dark bands are most likely the target protein but are not strongly 
binding like in the N-terminal 6X His-tagged INI1(31-144) gel. Figure 5 of C-terminus 6X His-
tagged INI1(31-144) also has dark bands below 15,000Da (std. curve = 15,445Da) in the cell 
extract and flow-through samples.  The calculated molecular weight is very close to the 
theoretical weight of the C-terminus 6X His-tagged INI1(31-144) protein, suggesting that the 6X 
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His-tag could be present but hidden, resulting in it not binding to the column. These results 
indicate that only a small amount of protein bound to the resin, suggesting that there is either a 
problem with the His-tag, the protein folding, the resin, or the conditions in which the protein 
bound. 
It is worth noting that a doublet appears around 100kDa on every gel. These are common 
contaminant proteins that are present when performing Ni-NTA affinity chromatography with 
pSKB3 vectors in E. coli cells. These proteins probably contain a stretch of Histidine residues or 
positively-charged residues that mimic a 6X His-tag.  
Overall, these four gels show that the location of the 6X His-tag on the INI1 protein does 
not matter, as both termini 6X His-tags in both INI1 truncations did not bind to the resin. 
Because of this finding, a series of binding tests were performed to determine if the protein did 
not bind to the resin because of the binding conditions of the solution or if there is another issue 
present. 
 
Purification Optimization Tests 
 Because binding relies on the presence of the 6X His-tag, there are two possibilities that 
could explain why the INI1 truncations did not strongly bind. The first is that the 6X His-tag is 
not on the protein. Although the presence of the 6X His-tag was verified when the plasmid was 
sequenced, it is possible that the E. coli expressed the INI1 truncations with the 6X His-tag 
attached but cleaved the 6X His-tag off during post-translational processing. The uncertainty of 
the SDS-PAGE, the uncertainty of the mathematical molecular weight calculation, and the small 
size of the 6X His-tag makes it difficult to declare that the 6X His-tag is missing based on 
molecular weight approximations alone. If the 6X His-tag is not present, the INI1 truncations 
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will not bind to the 6X His-tag specific resin. The other possibility is that the 6X His-tag is 
folded into the interior of the protein. Full-length INI1 labeled with 6X His-tag can be 
successfully purified using the Ni-NTA resin, suggesting that the 6X His-tag is present on the 
exterior of the full-length protein and able to bind to the resin. However, because both INI1 
truncations are shorter forms of the protein, it is possible that they fold differently due to the 
absence of additional hydrophobic and hydrophilic residues. 
  To test if either of these possibilities is the reason for the lack of binding, different types 
of denaturants/detergents as well as different buffer conditions were used. The first binding test 
shown in Figure 6 tested binding in unchanged conditions (control), half the buffer A 
concentration, urea lysis buffer, 10% SDS, Triton X-100, Tween 20, and Tween 80 to see if it 
affected the binding. There were several issues with this gel. The most obvious is that the Triton 
X-100, Tween 20, and Tween 80 lanes caused severe distortion of their lanes and surrounding 
lanes. This could be because Triton X-100, Tween 20, and Tween 80 are all non-ionic, 
hydrophobic detergents, which could explain the diffusion of the sample through the hydrophilic 
gel instead of towards the positive pole. This drift could also have been caused by too much 
Triton X-100, Tween 20, and Tween 80 in the samples themselves. These three detergents were 
too viscus to pipette normally so it is possible that too much Triton X-100, Tween 20, and Tween 
80 could have been the issue. In addition, when comparing the supernatant lane and the resin 
lane of the same condition, the proteins present are nearly identical. It is expected that the 
proteins missing from the supernatant lane should be the only proteins found in the resin lane; 
however, this is not the case with this gel. This is likely caused by loading the gel with standard 
P20 tips as their wide tip caused spill over into other wells. Lastly, when looking at the urea 
condition, it looks like the urea supernatant sample contains most of the desired protein. This is 
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worrisome because the urea binding condition result is the most reliable as a high urea 
concentration should completely denature the protein, thus revealing the 6X His-tag for binding. 
If the 6X His-tag is present, it is expected to cause the protein to strongly bind to the resin and 
have a dark band in the urea resin sample lane. However, this pattern was not observed. Because 
of these issues, the binding tests were repeated with tweaks to the procedure. 
 Figure 7 shows the results of the second binding attempt. Three changes were made to the 
procedure: 1) the Triton X-100, Tween 20, and Tween 80 conditions were removed to eliminate 
the risk of another distorted gel, 2) gel loading tips were used to load all samples onto the gel to 
minimize spill over, and 3) the resin tubes were flicked every 15 minutes during the binding step 
to ensure that the solution was properly mixed. A test lane (Lane 5) with non-resin-bound flow-
through INI1(31-125) was run to ensure that the samples are not the same. When comparing the 
prominent dark line in Lane 5 to the dark lines in Lanes 1-4, the band in Lane 5 is observed at a 
slightly lower molecular weight, indicating that the two samples do contain different INI1 
truncations.  
 The gel in Figure 7 is much neater than the gel in Figure 6, and spillover was kept to a 
minimum during loading of the gel. The Lanes 2-4 on the left of the gel are the supernatant 
samples while the right side of the gel contains the resin samples. There is no distinguishable 
band in any of the resin sample lanes, suggesting that the truncated INI1 protein did not bind to 
the resin under any of the conditions. Because the conditions contained denaturants, the 6X His-
tag should have been exposed, allowing the protein to bind. This data as well as the varying 
molecular weight discrepancies of both truncations suggest that the 6X His-tag is not present on 
the protein or is not functioning properly. If the 6X His-tag was present and fully-functioning, 
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there should have been more 6X His-tagged INI1 bound to the resin and in the resin lane of one 




 The most imminent goal is to find a way to isolate INI1(31-125) and INI1(31-144). From 
the findings, either the 6X His-tag is not present or the 6X His-tag is not functioning as intended. 
Because of this, a new purification approach must be used such as ion exchange chromatography 
or size-exclusion chromatography. The project cannot continue until an efficient purification 
procedure for these truncations is determined. A purification optimization test was not performed 
on the C-terminal 6X His-tagged INI1(31-144) or either INI1(31-125) sample. It is possible that 
these truncations might bind more to the resin than the N-terminal 6X His-tagged INI1(31-144). 
The eventual goal of this project is to isolate INI1(31-125) and INI1(31-144), potential 
DNA binding regions, and perform gel shift assays to determine if these domains bind DNA. 
Although this project did not reach this step, this is still the goal of the project and these tests will 
be completed in the future if effective purification techniques are discovered.  
The goal of studying INI1 is to determine its function and understand its mutation’s role 
in causing cancer. By determining its binding regions, researchers can better understand how 
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